Can Minimally Invasive Follicular Thyroid Cancer be Approached as a Benign Lesion?

Goffredo, Paolo; Cheung, Kevin; Roman, Sanziana A.; Sosa, Julie Ann

doi:10.1245/s10434-012-2697-4

Cited by 64 publications

(32 citation statements)

References 16 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(15) The report suggested that overall survival was comparable to the general population, and total thyroidectomy and RAI were not associated with improved outcomes. The authors, hence, advocated thyroid lobectomy for patients with MIFTC.…”

Section: Discussionmentioning

confidence: 97%

Hemithyroidectomy for low-risk follicular carcinoma of the thyroid: results from a regional hospital

Chow

Tam

Choi

et al. 2018

smedj

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Hemithyroidectomy for low-risk follicular carcinoma of the thyroid: results from a regional hospital

Chow

Tam

Choi

et al. 2018

smedj

View full text Add to dashboard Cite

show abstract

“…In particular, the MACIS system was based entirely on PTC, in contrast to AMES, which was based on any follicular cell derived, differentiated disease. Despite this, independent data from Lo et al 34 and review of the evidence 35,36 support the applicability of any of these systems to FTC.…”

Section: Discussionmentioning

confidence: 98%

“…Only a prospective, adjusted data series capturing human factor aspects of decision making, teamwork, surgical process, and outcomes at organisational and patient level would allow a definitive analysis of the interaction of perceived tumour risk, and decisions around operative interventions and related outcomes. For a disease whose natural history precludes the conventional acquisition of level I/II evidence, cumulative evidence as set out here and in similar studies 34,36 is currently the best available.…”

Section: Implications For Service and Practicementioning

confidence: 99%

A cross-specialty survey to assess the application of risk stratified surgery for differentiated thyroid cancer in the UK

Ramsay¹,

Fielding²,

Krukowski

2014

annals

View full text Add to dashboard Cite

INTRODUCTION This study describes variability of treatment for differentiated thyroid cancer among thyroid surgeons, in the context of changing patterns of thyroid surgery in the UK. METHODS Hospital Episodes Statistics on thyroid operations between 1997 and 2012 were obtained for England. A survey comprising six scenarios of varying 'risk' was developed. Patient/tumour information was provided, with five risk stratified or non-risk stratified treatment options. The survey was distributed to UK surgical associations. Respondent demographics were categorised and responses analysed by assigned risk stratified preference. RESULTS From 1997 to 2012, the Hospital Episode Statistics data indicated there was a 55% increase in the annual number of thyroidectomies with a fivefold increase in otolaryngology procedures and a tripling of cancer operations. Of the surgical association members surveyed, 264 respondents reported a thyroid surgery practice. Management varied across and within the six scenarios, and was not related consistently to the level of risk. Associations were demonstrated between overall risk stratified preference and higher volume practice (>25 thyroidectomies per year) (p=0.011), fewer years of consultant practice (p=0.017) and multidisciplinary team participation (p=0.037). Logistic regression revealed fewer years of consultant practice (odds ratio [OR]: 0.96/year in practice, 95% confidence interval [CI]: 0.922-0.997, p=0.036) and caseload of >25/year (OR 1.92, 95% CI: 1.044-3.522, p=0.036) as independent predictors of risk stratified preference. CONCLUSIONS There is a substantial contribution to thyroid surgery in the UK by otolaryngology surgeons. Adjusting management according to established case-based risk stratification is not widely applied. Higher caseload was associated with a preference for management tailored to individual risk.

show abstract

“…In addition, the differential histologic diagnosis of follicularpattern lesions, such as encapsulated FVPTC, minimally invasive follicular thyroid carcinoma (FTC), and other welldifferentiated tumors of uncertain malignant potential, is well documented and associated with a high interobserver variability in benign/malignant classification (28)(29)(30)(31). Local variations in the interpretation of histologic features can result in variable diagnostic rates of tumors with a low frequency of oncogenic mutations (e.g., encapsulated FVPTC or FTC) which, in turn, can affect the apparent diagnostic sensitivity of molecular testing (12,15,25,27,31).…”

Section: Discussionmentioning

confidence: 99%

Centralized Molecular Testing for Oncogenic Gene Mutations Complements the Local Cytopathologic Diagnosis of Thyroid Nodules

Beaudenon‐Huibregtse

Rb³

et al. 2014

Thyroid

121

107

View full text Add to dashboard Cite

Centralized and standardized molecular testing for genetic alterations associated with a high risk of malignancy efficiently complements the local cytopathologic diagnosis of thyroid nodule aspirates in the clinical setting. Actionable molecular cytology can improve the personalized surgical and medical management of patients with thyroid cancers, facilitating one-stage total thyroidectomy and reducing the number of unnecessary diagnostic surgeries.

show abstract

Can Minimally Invasive Follicular Thyroid Cancer be Approached as a Benign Lesion?

Abstract: MIFC is associated with survival comparable to that of the normative US general population. Thyroid lobectomy alone may be considered adequate treatment in these patients.

Cited by 64 publications

References 16 publications

Hemithyroidectomy for low-risk follicular carcinoma of the thyroid: results from a regional hospital

Hemithyroidectomy for low-risk follicular carcinoma of the thyroid: results from a regional hospital

A cross-specialty survey to assess the application of risk stratified surgery for differentiated thyroid cancer in the UK

Centralized Molecular Testing for Oncogenic Gene Mutations Complements the Local Cytopathologic Diagnosis of Thyroid Nodules

Contact Info

Product

Resources

About